34 results about "Withaferin A" patented technology

The present invention relates to an improved process of analytical and quantitative isolation of withaferin-A from Withania somnifera (Sanskrit: Ashwagandha, English: winter cherry) and other plants and products therefrom, said method comprising steps of selecting most appropriate extraction medium composition, with extraction solvent system consisting of a defined admixture of water and alcohol in a range of proportion of alcohol within a narrow range of (methanol, ethanol etc.) (preferably 60% alcohol and 40% water) for the dry plant material and from 60% to 80% alcohol in the alcohol-water mixture for fresh plant material, the invented extractant composition leading to better / improved yields and accurate quantitative estimations of withaferin A existent in planta or in materia, selecting effective state of the tissue particularly use of the fresh materials improving yields, providing logistic benefits of isolations and diagnosis, and according several other advantages including technological, economic, preventing contaminations etc., the said method being valuable and advantageous for standardization of botanicals, metabolomic characterization of plants particularly chemotypes, analyzing metabolic transitions under physiological, genetical, environmental and biotic perturbations.

The present invention relates to an improved process of analytical and quantitative isolation of withaferin-A from Withania somnifera (Sanskrit: Ashwagandha, English: winter cherry) and other plants and products therefrom, said method comprising steps of selecting most appropriate extraction medium composition, with extraction solvent system consisting of a defined admixture of water and alcohol in a range of proportion of alcohol within a narrow range of (methanol, ethanol etc.) (preferably 60% alcohol and 40% water) for the dry plant material and from 60% to 80% alcohol in the alcohol-water mixture for fresh plant material, the invented extractant composition leading to better / improved yields and accurate quantitative estimations of withaferin A existent in planta or in materia, selecting effective state of the tissue particularly use of the fresh materials improving yields, providing logistic benefits of isolations and diagnosis, and according several other advantages including technological, economic, preventing contaminations etc., the said method being valuable and advantageous for standardization of botanicals, metabolomic characterization of plants particularly chemotypes, analyzing metabolic transitions under physiological, genetical, environmental and biotic perturbations.

This invention describes a simple, rapid and cost-effective method to isolate bulk quantities of relatively pure and enriched anthocyanidins and other plant bioactives. The method is based on the principle of solubility. Some bioactives (anthocyanidins) were extracted in an aqueous solvent, transferred to a non-aqueous solvent and finally insolubilized by adding a miscible solvent in which the bioactive was insoluble. Thus, anthocyanidins were isolated from anthocyanin-enriched berries or non-enriched, dark-colored fruits, vegetables and grains by extraction of anthocyanins, acid hydrolysis, and extraction of the resulting anthocyanidins, followed by their insolubilization (precipitation). Some bioactives (hydrophobic and hydrophilic) were extracted in a solvent with high solubility and then directly insolubilized by adding a miscible solvent in which the bioactive was insoluble, for example, withaferin A from enriched Withania somnifera and punicalagins from enriched punica extract.

Method and compositions for reducing the inflammation after cytokine exposure of an islet cell transplant without affecting the viability and potency are disclosed herein. The present invention describes a composition comprising Withaferin A (WA), a steroidal lactone derived from Withania somnifera to effectively block NF-kB activation in beta cells, minimize cytokine-induced cell death and improve survival of transplanted islets. The method of the present invention involves identifying a subject having islet cells in need of treatment; and providing a effective amount of a Withaferin A composition disposed in a pharmaceutically acceptable carrier in an amount sufficient to reduce the inflammation after cytokine exposure without affecting the viability and potency of the islet cell population.

It is an object of the present invention to provide a method for preparing a water extract of ashwagandha, which comprises increasing the amounts of withanone and withaferin A contained as active ingredients in the water extract of ashwagandha leaves. In addition, it is another object of the present invention to more economically and simply provide a pharmaceutical composition comprising ashwagandha leaves.The present invention relates to a method for preparing a water extract of ashwagandha leaves, which comprises extracting ashwagandha leaves with water in the presence of cyclodextrin, and a method for enhancing the anticancer activity of the water extract of ashwagandha leaves. The present invention also relates to a pharmaceutical composition for treating or preventing cancer, comprising the water extract of ashwagandha leaves. The present invention further relates to a pharmaceutical composition comprising dry powders of ashwagandha leaves and cyclodextrin.

The present invention provides gero-protective pharmaceutical compositions and methods, the compositions being adapted to enhance at least one of cell survival and cell metabolism in a mammalian subject, the pharmaceutical compositions include at least two of Withaferin a or its structural analogs, coumestrol, ginsenoside, quinidine, silymarin, licochalcone a, lipoic acid and apigenin, in a pharmaceutically effective amount.

Novel withanolide chemical genetic probes identify the in vivo binding target of withaferin A, which is the intermediate filament type III protein vimentin. In addition, a withanolide-based small molecule screening method screens drug candidates that target intermediate filament type III proteins. The method includes introducing a tagged linker covalently bonded to the withanolide molecule to form a withanolide probe. Better or alternative small molecule compounds as potential drug candidates can be generated based on their likely affinity for the determined binding site in vimentin. The affinity labeled withanolide can also be used to find intermediate filament-associated proteins using chemical proteomics by extracting proteins from cells that were exposed to withanolide-biotin analog. The withanolide probes can be used to monitor expression of vimentin, in tumor samples or other diseased tissues. Withaferin analogs can be used as a treatment for diverse vimentin-associated disorders, such as cancers, angiofibrotic diseases, and chronic inflammation.

The invention discloses a combined drug preparation for treating pancreatic cancer. Withaferin A and oxaliplatin are used by the combined drug preparation for treating the pancreatic cancer. The Withaferin A and oxaliplatin can be used for killing cancer cells through oxidative stress injury mediated by the ROS (reactive oxygen species), two ROS in different sources can be united to develop the synergistic effect after combined medication, and the effect of killing pancreatic cancer cells is obvious stronger than that of single medication. Under the concentration in which the combined drug does not generate obvious toxic effect on the normal cells, the growth inhibiting effect of the combined drug on the pancreatic cancer cells is more obvious than that of clinical first drugs gemcitabine for the pancreatic cancer, the result shows that the combined drug can be well applied to treatment of the pancreatic cancer and preparation of the drugs for treating the pancreatic cancer.

A method of obtaining one or more fractions from a plant material of Withania somnifera (WS) is disclosed. The method includes subjecting the plant material to hydro-alcoholic extraction in presence of a water-insoluble solvent to obtain at least one extract. The method further includes subjecting the at least one extract obtained from the hydro-alcoholic extraction to at least one of de-pigmentation, de-fatting and detoxification process to obtain the one or more fractions. The one or more fractions thus obtained contain Withaferin A in a concentration greater than concentrations of other pharmacologically active ingredients present in the one or more fractions. The one or more fraction thus obtained and one or more compositions containing the one or more fractions are effective in inhibiting proliferation of mammalian cancerous cells.

The invention provides a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula I: wherein A, B, R1, R2, R10, and R11 are described herein, either alone or in combination with a second compound selected from elesclomol, NSC 174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1 152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

Weight loss agents include compounds defined by Formula I or a pharmaceutically acceptable salt or prodrug thereof, compositions containing the same, and methods of use thereof are described herein. In some embodiments, the compound is Withaferin A. In other embodiments, the compound is Michael addition product of Withaferin A. The compounds can be administered to induce weight loss in a pre-obese, obese, or morbidly obese patient, reduce body fat in a pre-obese, obese, or morbidly obese patient, reduce food intake in a pre-obese, obese, or morbidly obese patient, improve glucose homeostasis in a pre-obese, obese, or morbidly obese patient, or combinations thereof.

A method for prevention and / or treatment of diminution of bone tissue using a composition comprising a compound selected from Withaferin A (WFA), Withanolide A, and Withanone. The composition showed enhanced WFA bioavailability in rodents against plain WFA, promotes bone marrow cell differentiation, and increases the percent of bone volume to tissue volume (BV / TV%) by 3 folds as compared to free Withaferin A (WFA).

The invention relates to an anti-tumor medicament prepared for treating glioblastoma. The medicament refers to withaferin A, realizes the activity of resisting glioblastoma by inducing apoptosis, induces apoptosis of glioblastoma through a mitochondrial pathway, and activates the mitochondrial apoptosis pathway by upregulating the protein content of Bad and Bim.

A method for isolation of exosomes from bovine colostrum powder or goat colostrum powder, and the use of the isolated exosomes as nano carriers for small drug molecules, is described. Exosomes isolated from bovine colostrum powder averaged <85 nm in size, carried the surface-bound protein markers, Alix, TSG101, CD63 and CD81, and accepted various lipophilic (curcumin, withaferin A, paclitaxel) and hydrophilic (anthocyanidins) agents to serve as a nano carrier.

The invention discloses application of Withaferin A in preparing a drug for treating a fundus ischemic disease. Experiments show that the Withaferin A can inhibit the fundus ischemic disease from theperspective of pathogenesis through two mechanisms that 1, oxidative stress cell necrosis and apoptosis caused by ischemia are significantly reduced; 2, targeted inhibition of a vascular endothelial growth factor and a signaling pathway of a receptor (VEGF-VEGFR2) of the vascular endothelial growth factor is achieved, and the pathological microvascular hemorrhage leakage, abnormal blood vessel growth and other symptoms are ameliorated. The Withaferin A significantly relieves the symptoms of the fundus ischemic disease and inhibits the generation and development of the disease through the dualeffects of the two mechanisms. The Withaferin A as a small molecule targeting compound has a stable and safe chemical structure and can penetrate through a blood-eye barrier, therefore the WithaferinA has a broad application prospect in the fundus ischemic disease.

The invention discloses an application of withaferin A in preparation of an anti-tumor drug. The anti-tumor drug is used for treating lung cancer. A test result shows that the withaferin A can inhibit NSCLC cell proliferation, promote NSCLC cell apoptosis and inhibit NSCLC cell migration ability; and meanwhile, the combination of the withaferin A and erlotinib or the osimertinib can play a relatively strong synergistic effect, so that the effects of inhibiting NSCLC proliferation and promoting NSCLC apoptosis are achieved.

It is an object of the present invention to provide a method for preparing a water extract of ashwagandha, which comprises increasing the amounts of withanone and withaferin A contained as active ingredients in the water extract of ashwagandha leaves. In addition, it is another object of the present invention to more economically and simply provide a pharmaceutical composition comprising ashwagandha leaves.The present invention relates to a method for preparing a water extract of ashwagandha leaves, which comprises extracting ashwagandha leaves with water in the presence of cyclodextrin, and a method for enhancing the anticancer activity of the water extract of ashwagandha leaves. The present invention also relates to a pharmaceutical composition for treating or preventing cancer, comprising the water extract of ashwagandha leaves. The present invention further relates to a pharmaceutical composition comprising dry powders of ashwagandha leaves and cyclodextrin.

The invention provides a composition containing withaferin A, and relates to the technical field of medicines. The composition comprises topiramate and the withaferin A in a mass ratio of (1-25)*10<3>:1. Through the combined application of the topiramate and the withaferin A, the using amount of the topiramate and the withaferin A can be reduced, the side effects of the topiramate and the withaferin A can be obviously reduced, and the effects of reducing the body weight, improving the insulin sensitivity and optimizing the lipid metabolism more significantly can be achieved. The composition can still achieve the effects of significantly reducing the body weight, improving the insulin sensitivity and optimizing the lipid metabolism when the dosage is halved.

The invention provides a dietary supplement. The dietary supplement consists of the following components in parts by weight: 27-57 parts of a withania ketone extracat, 13-28 parts of a withaferin A extract, 5-20 parts of hydroxytyrosol, 5-20 parts of oleuropein and 5-20 parts of piperine. The dietary supplement provided by the invention can further consist of a nutrientologically and / or pharmaceutically acceptable carrier and / or adjuvants and can be prepared into the dosage form of an oral agent. The dietary supplement provided by the invention is outstanding in anti-inflammatory and anti-oxidant effects, and the dietary supplement can be further used for preparing health-care products and medicines.

Described is a natural product-containing supplement that enhances intracellular concentration of bioactive molecules through inhibition of MDR efflux pumps. Specifically described are dosage forms for administration to a subject, the dosage forms having at least four ingredients selected from the group consisting of apigenin, cannabidiol, chrysin, harmine, caffeic acid, piperine, nobiletin, Hypericum perforatum extract, bee propolis, oleanolic acid, biochanin, luteolin, vanillin, honokiol, pterostilbene, and withaferin A. Upon administration to a mammalian subject, the dosage forms generally inhibit mis-regulated MDR efflux pumps that are responsible for pushing out good nutrients from the cell—thus increasing intracellular concentration of health-promoting compounds.

The invention discloses application of Withaferin A in preparing a drug for treating a fundus ischemic disease. Experiments show that the Withaferin A can inhibit the fundus ischemic disease from theperspective of pathogenesis through two mechanisms that 1, oxidative stress cell necrosis and apoptosis caused by ischemia are significantly reduced; 2, targeted inhibition of a vascular endothelial growth factor and a signaling pathway of a receptor (VEGF-VEGFR2) of the vascular endothelial growth factor is achieved, and the pathological microvascular hemorrhage leakage, abnormal blood vessel growth and other symptoms are ameliorated. The Withaferin A significantly relieves the symptoms of the fundus ischemic disease and inhibits the generation and development of the disease through the dualeffects of the two mechanisms. The Withaferin A as a small molecule targeting compound has a stable and safe chemical structure and can penetrate through a blood-eye barrier, therefore the WithaferinA has a broad application prospect in the fundus ischemic disease.

The invention relates to a composition of withaferin A and leptin and an application of the composition to preparation of a medicine for preventing and / or treating hemorrhagic stroke, and belongs to the technical field of medicines. The invention provides the composition of the withaferin A and leptin and the application of the composition to preparation of the medicine for preventing and / or treating hemorrhagic stroke. The two existing compounds of the withaferin A and the leptin are applied to preparation of the medicine for preventing and / or treating hemorrhagic stroke through combinatorial optimization. The invention not only provides a new source for preparing the medicine for preventing and / or treating hemorrhagic stroke, but also explores new medicinal values of the withaferin A and the leptin. The technology disclosed by the invention is subsidized by the Guangxi science and technology base and the special talent fund (Guike AD18281013) and the Gangxi natural science fund youth fund (2018GXNSFBA138046) of the Gangxi natural science fund surface project (2020GXNSFA259036).

Disclosed are compounds of formula (I) and formula (II): (I) (II) wherein R1, R2, A, and B are as defined herein. Also disclosed is a method of blocking transmission of a Plasmodium parasite and a method of treating or preventing malaria comprising administering to an animal an effective amount of a first compound of formula (I) or (II) either alone or in combination with a second compound selected from elesclomol, NSC174938, NVP-AUY922, Maduramicin, Narasin, Alvespimycin, Omacetaxine, Thiram, Zinc pyrithione, Phanquinone, Bortezomib, Salinomycin sodium, Monensin sodium, Dipyrithione, Dicyclopentamethylene-thiuram disulfide, YM155, Withaferin A, Adriamycin, Romidepsin, AZD-1152-HQPA, CAY10581, Plicamycin, CUDC-101, Auranofin, Trametinib, GSK-458, Afatinib, and Panobinostat.

Described herein is a process of genetic transformation in W. somnifera by Agrobacterium tumefaciens mediated transformation to overexpress squalene synthase gene (WsSQS) encoding WsSQS enzyme that catalyzes the synthesis of squalene from farnesyl pyrophosphate. Increased withanolide level including withaferin-A, withanolide A and B and withanone is attained in transformed plant tissues.

The invention provides a medicinal composition containing withaferin A and an application thereof, which belong to the technical fields of medical science and biology. The medicinal composition comprises withaferin A and quercetin, the mass ratio of the withaferin A to quercetin is 1: (1 to 1500). In the present invention, the medicinal composition is possible to prevent and treat neurodegenerative diseases, protects neurons, improves the distribution and morphology of tyrosine hydroxylase-positive neurons in the mass ratio of withaferin A to quercetin, treats neuroinflammation, not only significantly reduces the usage dosage, but also achieves better results than single usage.